Fig. 8From: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancerDifferences in TME between R-O and S-O groups and between R-O+A and R-O groups. A The relative abundance of cell components was compared. B Differences in cell communication among the above cells. C Differences in function enrichment in those cell typesBack to article page